Early FDG-PET adapted treatment improves outcome in stage I /II Hodgkin’s lymphoma

July 28, 2015

Results from the randomized intergroup European Organisation for Research and Treatment of Cancer, Lymphoma Study Association and Fondazione Italiana Linfomi H10 trial have demonstrated that early FDG-PET adapted treatment improves outcomes of early FDG-PET-positive patients with stage I/II Hodgkin’s lymphoma (HL).

John Raemaekers (Radboud University Medical Center Nijmegen and, The Netherlands), the principal study coordinator, commented, “Even though the prognosis for patients with stage I/II HL is excellent if they are treated with the standard regimen of chemotherapy combined with radiotherapy, tumor control could still be improved for specific subgroups of patients, and late toxicity could be reduced for others.” 

Read the full story.